Development of SCP-1 to Treat Pain in the Elderly

Award Information
Agency:
Department of Health and Human Services
Amount:
$0.00
Program:
STTR
Contract:
2R42AG018196-02A1
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2003
Phase:
Phase I
Agency Tracking Number:
AG018196
Solicitation Topic Code:
N/A
Small Business Information
St. Charles Pharmaceuticals
2020 GRAVIER ST, 2020 GRAVIER ST, New Orleans, LA, 70112
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 KENNETH NARDUCY
 (408) 223-8748
 KNARDUCY@MSN.COM
Business Contact
 KENNETH NARDUCY
Phone: (504) 539-9276
Email: KNARDUCY@MSN.COM
Research Institution
 LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS
 2000 Lakeshore Drive
New Orleans, LA, 70148
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Acetaminophen is widely used for treatment of pain and/or fever in the elderly. This dual action is sometimes contraindicated. In many instances, pain needs to be controlled without masking the symptomatic fever (e.g., fever due to infection during the postoperative period). Acetaminophen can also cause hepatotoxicity, particularly after ingestion of large doses or chronic use of smaller doses (especially in the elderly or when liver function is affected), which can lead to death. Therefore, there is a need for new more selective compounds with greater pharmacological anti-pain potency and devoid of hepatotoxic or antipyretic effect. SCP-1 is the lead compound from St Charles Pharmaceutical's series of new proprietary derivatives of acetaminophen. SCP-1 has high analgesic activity but is free from antipyretic activity and hepatotoxicity In STTR Phase I, we explored the biological properties of SCP-1 in young and old animals. SCP-1 was effective and much less toxic than acetaminophen in young and old animals, and had an attractive pharmacokinetic profile. In STTR Phase II, we will further test and develop this drug in Phase II for treating pain in the elderly where acetaminophen is contraindicated. The analgesic properties of SCP-1 will be evaluated using two pain models: the Freund's Adjuvant inflammation assay and the formalin pain assay. We also will perform mechanism-of-action and pharmacokinetic studies using radiolabeled [14C] SCP-1.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government